Novo Nordisk to expand its diabetes sales force in the US by 60%  

2006.12.04
Danish healthcare company Novo Nordisk has announced plans to expand its diabetes sales force in the US by 700 people to 1,900, a 60% increase
Danish healthcare company Novo Nordisk, a world leader in diabetes care, has announced plans to expand its diabetes sales force in the US by 700 people to 1,900, a 60% increase. The aim of the expansion is to further strengthen Novo Nordisk's position in the US insulin market and to increase the company's 'share of voice' in the competitive market for diabetes products, Novo Nordisk writes in a press release. Novo Nordisk currently has a 40% share of the insulin market in the US and 60% in Europe
 
Share analysts estimate the costs of the expanded sales force to be around DKK 800 m (USD 144 m). Mike Rulis, head of communication at Novo Nordisk says: "The money has been calculated into our budgets, and has partly come from productivity improvements in other parts of the group." The expansion of the sales force is planned to take place during H1 2007.
 
Novo Nordisk is headquartered in Bagsværd, north of Copenhagen, and employs 23,000 people in 79 countries. The company has the broadest product portfolio in the diabetes industry, including advanced products in the area of insulin delivery systems. It also has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. 
 
The news was reported by financial daily newspaper Børsen.
 
Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×